Palisade Bio (PALI)
NASDAQ:PALI
Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.40
-$0.36(-15.79%)
At close: 4:00 PM EST
$2.40
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.86
Previous CloseN/A
Volume307.14K
Average Volume (3M)4.53M
Market Cap
$334.85M
Enterprise Value$201.53M
Total Cash (Recent Filing)$133.38M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta-0.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding167,424,210
10 Day Avg. Volume4,196,076
30 Day Avg. Volume4,525,639
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-201.53K
Enterprise Value/Ebitda-11.16
Forecast
1Y Price Target
$10.67Price Target Upside344.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Biomarker EvidenceAnalyst highlights coherent clinical responses across symptoms, biomarkers, endoscopy, and disease scoring, supporting the drug's potential anti-inflammatory and anti-fibrotic effects.
Oral Gut-targeted Formulation And SafetyAnalyst emphasizes the gut-activated oral prodrug design and favorable tolerability profile, which could offer an advantage over injectable therapies by reducing systemic side effects.
Unmet Medical Need And Commercial OpportunityAnalyst notes the absence of approved therapies for fibrostenotic Crohn's disease, indicating a clear unmet need and meaningful commercial upside if approval is achieved.
Bears Say
Microbiome-dependent Activation RiskAnalyst flags reliance on bacterial activation in the lower gut, so inflammation or shifts in the microbiome could change drug activation, exposure, and tolerability.
Open-label Design And Lack Of Placebo ControlAnalyst cautions that the open-label nature of the initial studies increases the risk that observed effects may not reproduce in larger, placebo-controlled trials.
Small Trial Size And Short Treatment DurationAnalyst warns that the very small patient cohort and limited treatment duration reduce confidence in the results and hinder assessment of broader clinical benefit.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.53 and its highest was $2.85 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $334.85M.
When is Palisade Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Palisade Bio’s earnings last quarter?
Currently, no data Available
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 167,424,210 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (344.44% Upside)
$10.67 (344.44% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.46%
12-Months-Change
Fundamentals
Return on Equity
-47.76%
Trailing 12-Months
Asset Growth
1134.78%
Trailing 12-Months
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$10.67
▲(344.44% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
0.03% Insiders
5.09% Mutual Funds
0.25% Other Institutional Investors
93.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---